Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00457938 · ClinicalTrials.gov registry record · NA

Novel Therapies for Metabolic Complications of Lipodystrophies

A NA study of Diabetes and Insulin Resistance, sponsored by University of Texas Southwestern Medical Center.

Completed
Registry status
NA
Development phase
4
Enrollment target
1
Study location

NCT00457938 is a NA study of Diabetes and Insulin Resistance that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 4 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00457938, a NA study of Diabetes and Insulin Resistance, has completed, sponsored by University of Texas Southwestern Medical Center.

COMPLETED
Registry status
NA
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

Lipodystrophies represent a therapeutic challenge with regards to the management of the diabetes, insulin resistance, hypertriglyceridemia and fatty liver which frequently present in conjunction with significant adipose tissue loss. The purpose of the study and it's four subprojects is to examine the safety and efficacy of various novel interventions designed to improve or resolve the fatty liver, hypertriglyceridemia, and insulin resistance or diabetes that is seen in these patients.

Interventions

  • OTHER Diet
  • OTHER low-fat diet ( Still recruiting )

Study Locations (1)

Texas

  • UT Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2006-04
Est. Completion 2014-11
Phase NA

What the Registry Record Tells You About NCT00457938

The ClinicalTrials.gov registry entry for NCT00457938 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (100% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Diet is the first listed.

NCT00457938 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00457938 about?

NCT00457938 is a clinical study titled "Novel Therapies for Metabolic Complications of Lipodystrophies". Lipodystrophies represent a therapeutic challenge with regards to the management of the diabetes, insulin resistance, hypertriglyceridemia and fatty liver which frequently present in conjunction with significant adipose tissue loss. The purpose of the study and it's four subprojects is to examine th...

What is the current status of trial NCT00457938?

This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2006-04. Estimated completion is 2014-11.

What conditions does trial NCT00457938 study?

This clinical trial studies the following conditions: Diabetes, Insulin Resistance, Hypertriglyceridemia, Hepatic Steatosis.

What interventions are being tested in trial NCT00457938?

The interventions under investigation include: Diet (OTHER), low-fat diet ( Still recruiting ) (OTHER).

Who is sponsoring clinical trial NCT00457938?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00457938 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.